中国保健营养（中旬刊）
中國保健營養（中旬刊）
중국보건영양（중순간）
China Hwalth Care & nutrition
2014年
6期
3616-3616
,共1页
晚期胃癌%雷替曲塞%多西他塞%奥沙利铂
晚期胃癌%雷替麯塞%多西他塞%奧沙利鉑
만기위암%뢰체곡새%다서타새%오사리박
advanced gastric cancer%raltitrexed%docetaxel%oxaliplatin
目的：探讨雷替曲塞联合多西他赛加奥沙利铂治疗晚期胃癌的临床疗效及其副作用。方法：选取我院57例经病理组织学证实的患者，随机分为2组：治疗组(28例)和对照组(29例)，分别予“雷替曲塞+奥沙利铂+多西他赛”方案和经典的FOLFOX4方案化疗。观察并评价两组治疗方案的疗效及副作用。结果：治疗组的疾病治疗有效率、控制率及中位疾病进展时间均高于对照组，有统计学差异(P<0.05)；但两组中位总生存时间未见明显差异，分别为8.3个月和7.9个月，无统计学差异(P>0.05)。此外，治疗组总的副作用发生率要高于对照组，多在可控制范围内。结论：雷替曲塞联合多西他赛加奥沙利铂治疗晚期胃癌安全有效，值得临床推广应用。
目的：探討雷替麯塞聯閤多西他賽加奧沙利鉑治療晚期胃癌的臨床療效及其副作用。方法：選取我院57例經病理組織學證實的患者，隨機分為2組：治療組(28例)和對照組(29例)，分彆予“雷替麯塞+奧沙利鉑+多西他賽”方案和經典的FOLFOX4方案化療。觀察併評價兩組治療方案的療效及副作用。結果：治療組的疾病治療有效率、控製率及中位疾病進展時間均高于對照組，有統計學差異(P<0.05)；但兩組中位總生存時間未見明顯差異，分彆為8.3箇月和7.9箇月，無統計學差異(P>0.05)。此外，治療組總的副作用髮生率要高于對照組，多在可控製範圍內。結論：雷替麯塞聯閤多西他賽加奧沙利鉑治療晚期胃癌安全有效，值得臨床推廣應用。
목적：탐토뢰체곡새연합다서타새가오사리박치료만기위암적림상료효급기부작용。방법：선취아원57례경병리조직학증실적환자，수궤분위2조：치료조(28례)화대조조(29례)，분별여“뢰체곡새+오사리박+다서타새”방안화경전적FOLFOX4방안화료。관찰병평개량조치료방안적료효급부작용。결과：치료조적질병치료유효솔、공제솔급중위질병진전시간균고우대조조，유통계학차이(P<0.05)；단량조중위총생존시간미견명현차이，분별위8.3개월화7.9개월，무통계학차이(P>0.05)。차외，치료조총적부작용발생솔요고우대조조，다재가공제범위내。결론：뢰체곡새연합다서타새가오사리박치료만기위암안전유효，치득림상추엄응용。
Objective:To investigate the clinical efficacy and side effects on raltitrexed combined docetaxel and oxaliplatin in the treatment of advanced gastric cancer.Methods:57 patients with histological diagnosis of advanced gastric cancer without treatment were randomly divided into 2 groups:the treatment group(including 28 patients)with the use of raltitrexed combined docetaxel and oxaliplatin and the control group(including 29 patients)with the use of classical FOLFOX4,and observe and evaluate the curative effect of two groups of treatment and side effects.Result:the treatment group had significantly higher response rate,beter disease control rate,and longer median time to disease progression cornpared with the control(P<0.05).But there was no difference in overal survival between the two(8.3 months vs 7.9 months)(P>0.05).In addition,the treatment group had higher side effects which could be controled.Conclusion:the use of raltitrexed combined docetaxel and oxaliplatin for the treatment of advanced gastric cancer is more beneficial to patients.
